Morepen Proposes Dividend After 23 Years, Logs Rs 1.18 Bn PAT in FY25
ECONOMY & POLICY

Morepen Proposes Dividend After 23 Years, Logs Rs 1.18 Bn PAT in FY25

In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (₹0.20 per share) after a gap of 23 years, marking a defining moment in the company’s four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.

The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.

Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”

Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.


Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (₹0.20 per share) after a gap of 23 years, marking a defining moment in the company’s four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

Next Story
Infrastructure Urban

Reliance, Diehl Advance Pact for Precision-Guided Munitions

Diehl Defence CEO Helmut Rauch and Reliance Group’s Founder Chairman Anil D. Ambani have held discussions to advance their ongoing strategic partnership focused on Guided and Terminally Guided Munitions (TGM), under a cooperation agreement originally signed in 2019.This collaboration underscores Diehl Defence’s long-term commitment to the Indian market and its support for the Indian Government’s Make in India initiative. The partnership’s current emphasis is on the urgent supply of the Vulcano 155mm Precision Guided Munition system to the Indian Armed Forces.Simultaneously, the “Vulc..

Next Story
Infrastructure Urban

Modis Navnirman to Migrate to Main Board, Merge Subsidiary

Modis Navnirman Limited has announced that its Board of Directors has approved a key strategic initiative involving migration from the BSE SME platform to the Main Board of both BSE and NSE, alongside a merger with its wholly owned subsidiary, Shree Modis Navnirman Private Limited.The move to the main boards marks a major milestone in the company’s growth trajectory, reflecting its consistent financial performance, robust corporate governance, and long-term commitment to value creation. This transition will grant the company access to a broader investor base, improve market participation, en..

Next Story
Infrastructure Urban

Global Capital Flows Remain Subdued, EMEA Leads in Q1 2025

The Bharat InvITs Association’s industry update for Q1 2025 shows subdued global capital flows, with investment volumes remaining at the lower end of the five-year range despite a late 2024 recovery. According to data from Colliers and MSCI Real Capital Analytics, activity in North America declined slightly, while EMEA maintained steady levels and emerged as the top region for investment in standing assets.The EMEA region now hosts seven of the top ten cross-border capital destinations for standing assets, pushing the United States’ share of global activity below 15 per cent. Meanwhile, in..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?